

JUL 13 2002

K021311

Summary

In accordance with the Food and Drug Administration Rule to implement provisions of the Safe Medical Devices Act of 1990 and in conformance with 21 CFR 807, this is to serve as a Summary of Safety and Effectiveness for the proposed CP Medical Monofilament spacer product.

Manufacturer:

CP Medical, Inc.
2414 NE Pacific Avenue
Portland, OR 97232
PHONE: (503) 232-1555
FAX: (503) 230-9993

Contact Person:

Mary Ann Greenawalt, Director Regulatory and Quality
or Sue Ridge, Regulatory Associate

Device Name:

Trade Name: Polydioxanone Synthetic Absorbable Seeding Spacers

Common Name: Accessory to applicator and accessory
to radionuclide brachytherapy Source

Proprietary name: Polydioxanone Synthetic Absorbable Seeding Spacers

Classification: System, applicator, radionuclide,
manual & Source, brachytherapy,
radionuclide (accessory to)

Date Prepared: April 17, 2002

Predicate Device: The predicate device to the CP Medical Polydioxanone Synthetic Absorbable Seeding Spacers is the CP Medical device, absorbable seeding spacers [K010621 and K013964].

Device Description: The CP Medical Polydioxanone Synthetic Absorbable Seeding Spacer consists of absorbable spacer material, which is cut into a small cylindrical seed spacer utilized to provide space between the radionuclide seeds as they are implanted into the body.

Intended Use: The CP Medical Polydioxanone Synthetic Absorbable Seeding Spacers are single-use, absorbable seeds comprised of spacer material used to provide a predetermined space between radionuclide seeds for brachytherapy procedures.

Indications: CP Medical's synthetic absorbable seeding spacers, made of polydioxanone material, are indicated for use in brachytherapy, soft tissue, or organ tissue but should not be used during cardiovascular or neurological procedures.

Food and Drug Administration
9200 Corporate Boulevard
Rockville MD 20850

JUL 13 2002

Ms. Mary Ann Greenawalt
Director, Regulatory
and Quality
CP Medical, Inc.
836 NE 24th Avenue
PORTLAND OR 97232

Re: K021311
Trade/Device Name: Synthetic Absorbable Seeding
Spacers made of Polydioxanone Material
Regulation Number: 21 CFR 892.5730
Regulation Name: Radionuclide brachytherapy source
Regulatory Class: II
Product Code: 90 KXX
Dated: April 17, 2002
Received: April 25, 2002

Dear Ms. Greenawalt:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (sections 531-542 of the Act); 21 CFR 1000-1050.


This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at one of the following numbers, based on the regulation number at the top of this letter:

8xx.1xxx	(301) 594-4591
876.2xxx, 3xxx, 4xxx, 5xxx	(301) 594-4616
884.2xxx, 3xxx, 4xxx, 5xxx, 6xxx	(301) 594-4616
892.2xxx, 3xxx, 4xxx, 5xxx	(301) 594-4654
Other	(301) 594-4692

Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address <http://www.fda.gov/cdrh/dsma/dsmamain.html>.

Sincerely yours,



Nancy C. Brogdon
Director, Division of Reproductive,
Abdominal, and Radiological Devices
Office of Device Evaluation
Center for Devices and Radiological Health

Enclosure

510(k) Number: K021311

Page 1 of 1

Device Name(s): Synthetic absorbable seeding spacer made of polydioxanone material

Indications for Use(s) of the Device:

CP Medical's synthetic absorbable seeding spacers made of polydioxanone material are indicated for use in brachytherapy, soft tissues, or organ tissue but should not be used during cardiovascular or neurological procedures.

Please do not write below this line - continue on another page if necessary

Concurrence of CDRH, Office of Device Evaluation (ODE)

Prescription Use ✓
(per 21 CFR 801.109)

or

Over-The-Counter Use _____

David A. Segerson
(Division Sign-Off)
Division of Reproductive, Abdominal,
and Radiological Devices
510(k) Number K021311